Obatala Sciences Moves Operations to Charleston
The biotech firm is relocating to Blue Sky Labs to expand its human stem cell research and drug testing capabilities.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Should medical research prioritize human-cell testing over animal models to better represent diverse patient populations?
Obatala Sciences is relocating its operations to Blue Sky Labs at the Medical University of South Carolina. The company uses human stem cells to develop organ-on-a-chip devices intended to replace traditional animal-based testing.
Why it matters
The company aims to enhance drug research relevance by utilizing diverse human-derived samples. This shift aligns with ongoing congressional efforts to transition away from animal-based testing methods.
Obatala Sciences operates a biobank containing 10,000 human cell samples sourced from 1,000 patients. The collection is notable for its demographic focus, with 80 percent of the samples derived from women.
The players
Obatala Sciences
A biotechnology company specializing in human-derived stem cell technology and organ-on-a-chip testing platforms.
Medical University of South Carolina
A public academic health science center in Charleston that hosts the Blue Sky Labs research facility.
South Carolina Department of Commerce
The state agency responsible for economic development, business recruitment, and the provision of infrastructure funding.
The details
The firm moved into renovated space at Blue Sky Labs using infrastructure funding facilitated by the South Carolina Department of Commerce. This expansion is part of a broader recruitment framework established by the state to attract life science companies.
Timeline
October 26, 2026: The company announces its move to Charleston.
Next 12 months: The company expects to complete its relocation from New Orleans.
The Tech Race
This move mirrors the industry-wide transition pushed by the FDA Modernization Act 3.0, which prioritizes human-cell derived products over legacy animal testing. It marks a departure from traditional drug research methods that have historically relied on animal models.
The relocation is expected to support a 10-fold increase in company size, potentially creating new regional employment opportunities in the life sciences sector. These advancements in testing technology may eventually lead to more effective drug therapies for the public.
The takeaway
The transition to human-cell derived testing represents a major shift toward more precise medical research. Residents and stakeholders should monitor the growth of this hub as it scales its operations over the coming year.
Further reading
Learn more about local industry trends in Charleston Biotech.
Source note: This article includes information reported by Post and Courier.
Live Poll
Should medical research prioritize human-cell testing over animal models to better represent diverse patient populations?
